Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2′,3′-dideoxycytidine) and BEA005 (2′,3′-dideoxy-3′-hydroxymethylcytidine) in rats, studied by microdialysis

被引:16
作者
Borg, N [1 ]
Ståhle, L [1 ]
机构
[1] Huddinge Hosp, Dept Clin Pharmacol, SE-14186 Huddinge, Sweden
关键词
D O I
10.1128/AAC.42.9.2174
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2',3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (C-max) was 31.4 +/- 5.1 mu M (mean +/- standard error of the mean) for the brain and 238.3 +/- 48.1 mu M for muscle. The time to C-max was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037, The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with C(max)s of 5.7 +/- 1.4 mu M in the brain and 61.3 +/- 12.0 mu M in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026, The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0,481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).
引用
收藏
页码:2174 / 2177
页数:4
相关论文
共 26 条
[1]  
[Anonymous], 1984, Measurement of Neurotransmitter ReleaseIn Vivo
[2]   Distribution to the brain and protein binding of 3' and 5-substituted 2',3'-dideoxyuridine derivatives, studied by microdialysis [J].
Borg, N ;
Zhou, XX ;
Johansson, NG ;
Oberg, B ;
Stahle, L .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (01) :47-53
[3]   Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005 [J].
Bottiger, D ;
Johansson, NG ;
Samuelsson, B ;
Zhang, H ;
Putkonen, P ;
Vrang, L ;
Oberg, B .
AIDS, 1997, 11 (02) :157-162
[4]  
Bradbury M., 1979, CONCEPT BLOOD BRAIN
[5]   PHARMACODYNAMICS OF 2',3'-DIDEOXYCYTIDINE - AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BRODER, S .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (5B) :S2-S7
[6]  
COLLINS JM, 1988, J PHARMACOL EXP THER, V245, P466
[7]   ZALCITABINE - CLINICAL PHARMACOKINETICS AND EFFICACY [J].
DEVINENI, D ;
GALLO, JM .
CLINICAL PHARMACOKINETICS, 1995, 28 (05) :351-360
[8]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE ANALYSIS OF 2',3'-DIDEOXYCYTIDINE IN HUMAN PLASMA [J].
HAWKINS, ME ;
POPLACK, DG ;
PIZZO, PA ;
BALIS, FM .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 532 (02) :442-444
[9]   NOVEL NUCLEOSIDE STRATEGIES FOR ANTI-HIV AND ANTI-HSV THERAPY [J].
HERDEWIJN, PAMM .
ANTIVIRAL RESEARCH, 1992, 19 (01) :1-14
[10]   MICRODIALYSIS SAMPLING FOR DETERMINATION OF PLASMA-PROTEIN BINDING OF DRUGS [J].
HERRERA, AM ;
SCOTT, DO ;
LUNTE, CE .
PHARMACEUTICAL RESEARCH, 1990, 7 (10) :1077-1081